Literature DB >> 21570062

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Ekambar R Kandimalla1, Mary Struthers, Andrew J Bett, Thomas Wisniewski, Sheri A Dubey, Weiwen Jiang, Melissa Precopio, Zhenhua Sun, Hao Wang, Tao Lan, Sudhir Agrawal, Danilo R Casimiro.   

Abstract

Single-stranded oligoribonucleotides (ORNs) stimulate innate immune responses through TLR7 and TLR8. Specific linkages and chemical modifications incorporated into synthetic ORN can greatly enhance nuclease stability, selectivity, and potency. In the present study, we have synthesized 15 ORN containing different sequence compositions and chemical modifications and studied their TLR7- and TLR8-mediated immune response profiles in HEK293 cells expressing human TLR7 or TLR8, human PBMCs, mDCs and pDCs, non-human primate (NHP) PBMCs, and in vivo in mice and NHPs. Based on the results obtained, eight of the ORNs containing specific chemical modifications induced immune responses through both TLR7 and TLR8, including activation of NF-κB in TLR7- and TLR8-transfected cell lines; induction of IFN-α, IL-6, TNF-α, IL-12, and IP-10 in human PBMCs; IFN-α induction in human pDCs; CD80 upregulation in human pDCs and mDCs; IL-12 induction following acute administration in mice; IFN-α, IP-10, IL-6, and IL-12 induction in NHP PBMCs; and IFN-α, IP-10, and IL-6 induction following acute administration in NHPs. Seven of the ORNs show selectivity for TLR8-induced responses; they specifically activate only TLR8-transfected cell lines, induce cytokines other than IFN-α in human and NHP PBMCs, activate mDCs more than pDCs, and do not induce IL-12 acutely in mice, consistent with the lack of functional TLR8 in mice. The novel TLR8-selective ORNs also induce cytokines other than IFN-α acutely in NHPs. In conclusion, we have designed and synthesized novel ORNs with varying sequence compositions and chemical modifications, which selectively act as agonists of TLR8 or dual agonists of TLR7 and TLR8.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570062     DOI: 10.1016/j.cellimm.2011.03.027

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  RAGE Enhances TLR Responses through Binding and Internalization of RNA.

Authors:  Damien Bertheloot; Allison L Naumovski; Pia Langhoff; Gabor L Horvath; Tengchuan Jin; Tsan Sam Xiao; Natalio Garbi; Sudhir Agrawal; Roland Kolbeck; Eicke Latz
Journal:  J Immunol       Date:  2016-10-19       Impact factor: 5.422

Review 2.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

Review 3.  Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.

Authors:  Sudhir Agrawal; Ekambar R Kandimalla
Journal:  Immunooncol Technol       Date:  2019-10-16

Review 4.  Injection site reactions after subcutaneous oligonucleotide therapy.

Authors:  Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

5.  Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer.

Authors:  Nikunj M Shukla; Deepak B Salunke; Rajalakshmi Balakrishna; Cole A Mutz; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.